• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Asthma research and practice. >Asthma management with breath-triggered inhalers: innovation through design
【24h】

Asthma management with breath-triggered inhalers: innovation through design

机译：哮喘管理与呼吸触发吸入器：通过设计创新

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background:Asthma affects the lives of hundred million people around the World. Despite notable progresses in disease management, asthma control remains largely insufficient worldwide, influencing patients' wellbeing and quality of life. Poor patient handling of inhaling devices has been identified as a major persistent problem that significantly reduces inhaled drugs' efficacy and is associated with poor adherence to treatment, impairing clinical results such as asthma control and increasing disease-related costs. We herein review key research and development (R&D) innovation in inhaler devices, highlighting major real-world critical errors in the handling and inhalation technique with current devices and considering potential solutions. Furthermore, we discuss current evidence regarding breath-triggered inhalers (BTI).Main body:The two most common significant problems with inhalers are coordinating actuation and inhalation with pressurized metered-dose inhalers (pMDIs), and the need to inhale forcibly with a dry powder inhaler. BTI R&D plans were designed to overcome these problems. Its newest device k-haler? has several other important features, generating a less forceful aerosol plume than previous pMDIs, with efficient drug delivery and lung deposition, even in patients with low inspiratory flow. The local and systemic bioavailability of fluticasone propionate and formoterol (FP/FORM) administered via k-haler? has been shown to be therapeutically equivalent when administered via the previous FP/FORM pMDI. This device requires very few steps and has been considered easy to use (even at first attempt) and preferred by the patients in a randomized crossover study. In our country, FP/FORM k-haler is available without additional costs compared to FP/FORM pMDI. All devices continue to require education and regular checking of the correct inhalation technique.Conclusion:BTI R&D can bring advantage over current available inhalers, avoiding the two most common identified critical errors in inhalation technique. K-haler? BTI is currently available, without an increased cost, and approved for adolescents and adults with asthma in whom treatment with inhaled combined therapy with long-acting beta2-agonists and corticosteroids is indicated. Its attractive and practical design to facilitate its use has been awarded. K-haler? represents added value through innovation to fulfill actual asthma patient needs, thus with potential relevant impact in asthma management and effective control.? The Author(s) 2020.
机译：背景：哮喘影响世界各地亿人的生命。尽管疾病管理有显着进展，但哮喘控制仍然在全球范围内仍然不足，影响患者的幸福和生活质量。患者吸入装置的患者处理较差被认为是一个主要的持续存在问题，可显着降低吸入药物的疗效，并且与对治疗的不良粘附相关，损害哮喘控制等临床结果损害和增加的疾病相关的成本。我们在此综述重点研发（研发）吸入器设备的创新，突出了处理和吸入技术的主要实际临界误差，并考虑了潜在的解决方案。此外，我们讨论了有关呼吸触发吸入器（BTI）的现有证据.Main身体：吸入器的两个最常见的重要问题是使用加压计量吸入器（PMDIS）配等驱动和吸入，并且需要用干燥吸入粉末吸入器。 BTI研发计划旨在克服这些问题。它最新的设备k-aller？具有几个其他重要特征，产生比以前的PMDIS更不强烈的气溶胶羽毛，即使在低吸气流动的患者中，甚至是有效的药物递送和肺部沉积。通过K-almer施用氟替卡松丙酸酯和甲酚（FP /形式）的局部和全身性生物利用度？通过先前的FP /型PMDI施用时已被证明是治疗相同的。该装置需要很少的步骤，并且已被认为易于使用（甚至首先尝试），并且在随机交叉研究中优先于患者。与FP / FORM PMDI相比，在我们国家/地区，无需额外费用即可提供FP / Form K-Haler。所有设备都不断要求教育和定期检查正确的吸入技术。结论：BTI研发可以利用电流吸入器，避免吸入技术中最常见的两个最常见的关键误差。 K-al aler？目前，BTI目前可用，没有增加成本，并批准用于哮喘的青少年和成年人，其中有吸入的β2-激动剂和皮质类固醇的吸入治疗治疗。它有吸引力和实用的设计，以促进其使用已被授予。 K-al aler？通过创新表示增加的价值，以满足实际的哮喘患者需求，因此对哮喘管理和有效控制具有潜在的相关影响。作者2020年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号